.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization

Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
Digital.CSIC. Repositorio Institucional del CSIC
  • Guardo, Alberto C
  • Gómez, Carmen Elena
  • Díaz-Brito, Vicens
  • Pich, Judit
  • Arnaiz, Joan Albert
  • Perdiguero, Beatriz
  • GARCIA ARRIAZA, JUAN FRANCISCO
  • González, Nuria
  • Sorzano, Carlos O S
  • Jiménez, Laura
  • Jiménez, José Luis
  • Muñoz-Fernández, María Ángeles
  • Gatell, José M
  • Alcamí, José
  • Esteban, Mariano
  • López Bernaldo de Quirós, Juan Carlos
  • García, Felipe
  • Plana, Montserrat
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost., Peer reviewed
 
DOI: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717

HANDLE: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
 
Ver en: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717

Dipòsit Digital de la UB
oai:diposit.ub.edu:2445/175207
Artículo científico (article). 2017

SAFETY AND VACCINE-INDUCED HIV-1 IMMUNE RESPONSES IN HEALTHY VOLUNTEERS FOLLOWING A LATE MVA-B BOOST 4 YEARS AFTER THE LAST IMMUNIZATION

Dipòsit Digital de la UB
  • Crespo Guardo, Alberto
  • Gómez, Carmen Elena
  • Díaz Brito, Vicens
  • Pich, Judit
  • Arnaiz Gargallo, Juan Alberto
  • Perdiguero, Beatriz
  • García Arriaza, Juan
  • GonzÁlez, Núria
  • Sorzano, Carlos O. S.
  • Jiménez, Laura
  • Jiménez, José Luis
  • Muñoz Fernández, María Ángeles
  • Gatell, José M.
  • Alcamí, José
  • Esteban, Mariano
  • López Bernaldo de Quirós, Juan Carlos
  • García Alcaide, Felipe
  • Plana Prades, Montserrat
  • RISVAC02boost study
Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector.




Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
. 2017

SAFETY AND VACCINE-INDUCED HIV-1 IMMUNE RESPONSES IN HEALTHY VOLUNTEERS FOLLOWING A LATE MVA-B BOOST 4 YEARS AFTER THE LAST IMMUNIZATION

Digital.CSIC. Repositorio Institucional del CSIC
  • Guardo, Alberto C
  • Gómez, Carmen Elena
  • Díaz-Brito, Vicens
  • Pich, Judit
  • Arnaiz, Joan Albert
  • Perdiguero, Beatriz
  • GARCIA ARRIAZA, JUAN FRANCISCO
  • González, Nuria
  • Sorzano, Carlos O S
  • Jiménez, Laura
  • Jiménez, José Luis
  • Muñoz-Fernández, María Ángeles
  • Gatell, José M
  • Alcamí, José
  • Esteban, Mariano
  • López Bernaldo de Quirós, Juan Carlos
  • García, Felipe
  • Plana, Montserrat
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost., Peer reviewed




r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
oai:fundanet.fsjd.org:p14292
Artículo científico (article). 2017

SAFETY AND VACCINE-INDUCED HIV-1 IMMUNE RESPONSES IN HEALTHY VOLUNTEERS FOLLOWING A LATE MVA-B BOOST 4 YEARS AFTER THE LAST IMMUNIZATION.

r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
  • Guardo AC
  • Gómez CE
  • Díaz-Brito V
  • Pich J
  • Arnaiz JA
  • Perdiguero B
  • García-Arriaza J
  • González N
  • Sorzano COS
  • Jiménez L
  • Jiménez JL
  • Muñoz-Fernández MÁ
  • Gatell JM
  • Alcamí J
  • Esteban M
  • López Bernaldo de Quirós JC
  • García F
  • Plana M
  • RISVAC02boost study
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost.



Repisalud
oai:repisalud.isciii.es:20.500.12105/6880
Artículo científico (article). 2017

SAFETY AND VACCINE-INDUCED HIV-1 IMMUNE RESPONSES IN HEALTHY VOLUNTEERS FOLLOWING A LATE MVA-B BOOST 4 YEARS AFTER THE LAST IMMUNIZATION

Repisalud
  • Guardo, Alberto C
  • Gómez, Carmen Elena
  • Díaz-Brito, Vicens
  • Pich, Judit
  • Arnaiz, Joan Albert
  • Perdiguero, Beatriz
  • García-Arriaza, Juan
  • Gonzalez-Fernandez, Nuria
  • Sorzano, Carlos O S
  • Jiménez, Laura
  • Jiménez, José Luis
  • Muñoz-Fernández, María Ángeles
  • Gatell, José M
  • Alcamí, José
  • Esteban, Mariano
  • López Bernaldo de Quirós, Juan Carlos
  • García, Felipe
  • Plana, Montserrat
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS One. 2018 Apr 10;13(4):e0195915. doi: 10.1371/journal.pone.0195915. PMID: 29634751, BACKGROUND: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. METHODS: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. RESULTS: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. CONCLUSIONS: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector. TRIAL REGISTRATION: ClinicalTrials.gov NCT01923610., This study was partially supported by grants: FIS PI12/00969, PI15/00480, SAF2015-66193-R., EC10-153, TRA-094, RIS, HIVACAT, SAF2013-45232-R. RIS: Red Temática Cooperativa de Grupos de Investigación en Sida del Fondo de Investigación Sanitaria (FIS). HIVACAT: HIV development program in Catalonia. IDIBAPS: Institut d’Investigacions Biomèdiques August Pi I Sunyer., Sí




Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/29986
Artículo científico (article). 2017

SAFETY AND VACCINE-INDUCED HIV-1 IMMUNE RESPONSES IN HEALTHY VOLUNTEERS FOLLOWING A LATE MVA-B BOOST 4 YEARS AFTER THE LAST IMMUNIZATION.

Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
  • Guardo, Alberto C
  • Gómez, Carmen Elena
  • Díaz-Brito, Vicens
  • Pich, Judit
  • Arnaiz, Joan Albert
  • Perdiguero, Beatriz
  • García-Arriaza, Juan
  • González, Nuria
  • Sorzano, Carlos O S
  • Jiménez, Laura
  • Jiménez, José Luis
  • Muñoz-Fernández, María Ángeles
  • Gatell, José M
  • Alcamí, José
  • Esteban, Mariano
  • López Bernaldo de Quirós, Juan Carlos
  • García, Felipe
  • Plana, Montserrat
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost.




1106